Patient characteristics
| Variable . | Sirolimus/Tacrolimus . | Tacrolimus/Methotrexate . | P . |
|---|---|---|---|
| Number of patients | 151 | 153 | — |
| Underwent transplantation | 149 (99) | 152 (99) | .55 |
| Age, median (range) | 45 (19-59) | 43 (13-58) | .40 |
| Male gender | 77 (51) | 85 (56) | .43 |
| Primary malignancy | .05 | ||
| Acute myelogenous leukemia | 71 (47) | 63 (41) | |
| Acute lymphoblastic leukemia | 51 (34) | 68 (44) | |
| Chronic myelogenous leukemia | 9 (6) | 14 (9) | |
| Myelodysplastic syndrome | 19 (13) | 7 (5) | |
| Acute biphenotypic leukemia | 1 (<1) | 1 (<1) | |
| Disease status at transplantation | |||
| Acute myelogenous leukemia | .55 | ||
| 1st complete remission | 60 (85) | 56 (89) | |
| 2nd complete remission | 11 (15) | 7 (11) | |
| Acute lymphoblastic leukemia | .90 | ||
| 1st complete remission | 41 (80) | 55 (81) | |
| 2nd complete remission | 10 (20) | 13 (19) | |
| Chronic myelogenous leukemia | .74 | ||
| Chronic phase | 7 (78) | 10 (71) | |
| Accelerated phase | 2 (22) | 4 (29) | |
| Acute biphenotypic leukemia | |||
| 1st complete remission | 1 | 1 | |
| Karnofsky score | .09 | ||
| 90% to 100% | 101 (67) | 116 (76) | |
| <90% | 50 (33) | 37 (24) | |
| Recipient-donor CMV status | .16 | ||
| +/+ | 59 (39) | 47 (31) | |
| +/− | 14 (9) | 24 (16) | |
| −/+ | 30 (20) | 44 (29) | |
| −/− | 38 (25) | 30 (20) | |
| Missing | 10 (7) | 8 (5) | |
| Donor-recipient gender match | .63 | ||
| Female-male | 33 (27) | 30 (20) | |
| Conditioning regimen | |||
| CY/TBI | 124 (82) | 122 (80) | .60 |
| Etoposide/TBI | 27 (18) | 31 (20) |
| Variable . | Sirolimus/Tacrolimus . | Tacrolimus/Methotrexate . | P . |
|---|---|---|---|
| Number of patients | 151 | 153 | — |
| Underwent transplantation | 149 (99) | 152 (99) | .55 |
| Age, median (range) | 45 (19-59) | 43 (13-58) | .40 |
| Male gender | 77 (51) | 85 (56) | .43 |
| Primary malignancy | .05 | ||
| Acute myelogenous leukemia | 71 (47) | 63 (41) | |
| Acute lymphoblastic leukemia | 51 (34) | 68 (44) | |
| Chronic myelogenous leukemia | 9 (6) | 14 (9) | |
| Myelodysplastic syndrome | 19 (13) | 7 (5) | |
| Acute biphenotypic leukemia | 1 (<1) | 1 (<1) | |
| Disease status at transplantation | |||
| Acute myelogenous leukemia | .55 | ||
| 1st complete remission | 60 (85) | 56 (89) | |
| 2nd complete remission | 11 (15) | 7 (11) | |
| Acute lymphoblastic leukemia | .90 | ||
| 1st complete remission | 41 (80) | 55 (81) | |
| 2nd complete remission | 10 (20) | 13 (19) | |
| Chronic myelogenous leukemia | .74 | ||
| Chronic phase | 7 (78) | 10 (71) | |
| Accelerated phase | 2 (22) | 4 (29) | |
| Acute biphenotypic leukemia | |||
| 1st complete remission | 1 | 1 | |
| Karnofsky score | .09 | ||
| 90% to 100% | 101 (67) | 116 (76) | |
| <90% | 50 (33) | 37 (24) | |
| Recipient-donor CMV status | .16 | ||
| +/+ | 59 (39) | 47 (31) | |
| +/− | 14 (9) | 24 (16) | |
| −/+ | 30 (20) | 44 (29) | |
| −/− | 38 (25) | 30 (20) | |
| Missing | 10 (7) | 8 (5) | |
| Donor-recipient gender match | .63 | ||
| Female-male | 33 (27) | 30 (20) | |
| Conditioning regimen | |||
| CY/TBI | 124 (82) | 122 (80) | .60 |
| Etoposide/TBI | 27 (18) | 31 (20) |